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Long-term effects of angiotensin-converting enzyme inhibition
and metabolic control in hypertensive type 2 diabetic patients
JULIANA C.N. CHAN, GARY T.C. KO, DENIS H.Y. LEUNG, ROBERT C.K. CHEUNG,
MARGARET Y.F. CHEUNG, WING-YEE SO, RAMASMYIYER SWAMINATHAN, M. GARY NICHOLLS,
JULIAN A.J.H. CRITCHLEY, and CLIVE S. COCKRAM
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital,
Shatin, Hong Kong
in the nifedipine group (N 5 13). In the macroalbuminuricLong-term effects of angiotensin-converting enzyme inhibition
patients, enalapril treatment (N 5 11) was associated withand metabolic control in hypertensive type 2 diabetic patients.
stabilization compared with a decline in renal function in theBackground. In hypertensive type 2 diabetic patients, treat-
nifedipine group, as shown by the b-1/Cr (0.65 6 4.29 vs.ment with angiotensin-converting enzyme (ACE) inhibitors is
21.93 6 2.35 1/mmol 3 1023, P , 0.05) after adjustment forassociated with a lower incidence of cardiovascular events than
those treated with calcium channel-blocking agents. However, baseline values. Compared with the normoalbuminuric and
the long-term renal effects of ACE inhibitors in these patients microalbuminuric patients, those with macroalbuminuria had
remain inconclusive. In 1989, we commenced a placebo-con- the lowest mean CCr (75.5 6 24.1 vs. 63.5 6 21.3 vs. 41.9 6
trolled, double-blind, randomized study to examine the anti- 18.5 mL/min, P , 0.001) and the highest frequency of clinical
albuminuric effects of enalapril versus nifedipine (slow release) events (4.7 vs. 5.9 vs. 52%, P , 0.001). On multivariate analysis,
in 102 hypertensive, type 2 diabetic patients. These patients b-1/Cr (R2 5 0.195, P , 0.001) was independently associated
have been followed up for a mean trial duration of 5.5 6 2.2 with baseline HbA1c (b 5 20.285, P 5 0.004), whereas clinical
years. We examined the determinants, including the effect of outcomes (R2 5 0.176, P , 0.001) were independently related
ACE inhibition on clinical outcomes in these patients. to the mean low-density lipoprotein cholesterol (b 5 2.426, P 5
Methods. After a six-week placebo-controlled, run-in pe- 0.018), high-density lipoprotein cholesterol (b 5 28.797, P 5
riod, 52 patients were randomized double-blind to receive 0.03), baseline UAE (b 5 0.002, P 5 0.04), and mean CCr
nifedipine (slow release) and 50 patients to receive enalapril. during treatment (b 5 20.211, P 5 0.006).
After the one-year analysis, which confirmed the superior anti- Conclusion. In this prospective cohort analysis involving 102
albuminuric effects of enalapril (254%) over nifedipine hypertensive, type 2 diabetic patients with varying degrees of
(111%), all patients were continued on their previously as- albuminuria followed up for a mean duration of five years, we
signed treatment with informed consent. They were subdivided observed the importance of good metabolic and blood pressure
into normoalbuminuric (N 5 43), microalbuminuric (N 5 34), control on the progression of albuminuria and renal function.
and macroalbuminuric (N 5 25) groups based on two of three Treatment with enalapril was associated with a greater reduc-
24-hour urinary albumin excretion (UAE) measurements tion in albuminuria than with nifedipine in the entire patient
during the run-in period. Renal function was shown by the group, and especially in those with microalbuminuria. In the
24-hour UAE, creatinine clearance (CCr), and the regression macroalbuminuric patients, the rate of deterioration in renal
coefficient of the yearly plasma creatinine reciprocal (b-1/Cr). function was also attenuated by treatment with enalapril.
Clinical endpoints were defined as death, cardiovascular events,
and/or renal events (need for renal replacement therapy or
doubling of baseline plasma creatinine).
Results. In the whole group, patients treated with enalapril The coexistence of hypertension in diabetic patients
were more likely to revert to being normoalbuminuric (23.8 markedly increases cardiovascular risks and the rate of
vs. 15.4%), and fewer of them developed macroalbuminuria
deterioration of renal function [1, 2]. On the other hand,(19.1 vs. 30.8%) compared with the nifedipine-treated patients
optimal control of blood pressure (BP) and metabolic(P , 0.05). In the microalbuminuric group, treatment with
enalapril (N 5 21) was associated with a 13.0% (P , 0.01) parameters has been shown to reduce cardiovascular and
reduction in 24-hour UAE compared with a 17.3% increase renal deaths [2–7]. Angiotensin II has major effects on
renal hemodynamics and cellular growth [8]. Treatment
with angiotensin-converting enzyme (ACE) inhibitors isKey words: renal hemodynamics, cardiovascular disease, blood pres-
sure, albuminuria, enalapril, nifedipine. associated with a reduction of proteinuria in both type
1 and type 2 diabetic patients, an effect independent ofReceived for publication December 17, 1998
the degree of BP reduction [9]. This class of drug hasand in revised form July 27, 1999
Accepted for publication August 13, 1999 also been shown to reduce the rate of deterioration of
renal function in both type 1 [10] and normotensive typeÓ 2000 by the International Society of Nephrology
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2 diabetic patients [11, 12]. However, in hypertensive plasma creatinine of greater than 200 mmol/L. All pa-
tients gave written informed consent and underwent his-type 2 diabetic patients, the possible beneficial effects
of ACE inhibitors over other antihypertensive drugs re- tory taking and physical examination.
Patients fulfilling the inclusion criteria who had a su-main controversial.
In the few long-term studies, lasting one year or more, pine BP $ 150/95 mm Hg or were established on antihy-
pertensive drugs entered a six-week placebo-controlled,that aimed to examine the renal effects of ACE inhibitors
in hypertensive type 2 diabetic patients, ACE inhibitor run-in period, after withdrawal of all antihypertensive
drug therapy, if any. BP was measured after five minutestreatment had similar effects on the progression of renal
function as other antihypertensive drugs, including cal- of lying (supine) and two minutes of standing (erect),
with two readings in each position at one minute apart.cium channel-blocking agents [13–15]. In the United
Kingdom Prospective Diabetes Study (UKPDS), inten- The mean arterial pressure (MAP) was defined as dia-
stolic BP plus one third of the difference between systolicsive control of BP was associated with reduced mortality
[16], which was not different between patients treated and diastolic BP, and the mean of the supine and erect
BP values was used. During the six-week run-in period,with captopril or atenolol [17]. On the other hand, two
other studies have confirmed a lower incidence of cardio- fasting blood was sampled for routine biochemistry, and
24-hour urinary collections were made on three occa-vascular events in patients treated with ACE inhibitors
(enalapril or fosinopril) than those treated with calcium sions for measurement of endogenous creatinine clear-
ance (CCr) and UAE. All patients received placebo tab-channel-blocking agents (nisoldipine or amlodipine) in
hypertensive type 2 diabetic patients [18, 19]. In these lets matching for enalapril 10 mg daily and nifedipine
(slow release) 20 mg twice daily.two relatively short-term studies, the renal effects of the
ACE inhibitors in these patients were inconclusive. At the end of the six-week run-in period, patients with
a mean supine systolic BP between 150 and 220 mm HgIn 1989, we commenced a randomized, double-blind,
placebo-controlled study to examine the effects of enala- and/or diastolic BP $ 100 mm Hg were randomized in
a double-blind fashion to receive active treatment withpril versus nifedipine (slow release) on urinary albumin
either enalapril 10 mg once daily or nifedipine (slowexcretion (UAE) in 102 hypertensive type 2 diabetic
release) 20 mg twice daily with matching placebo tabletspatients with preserved renal function. At one year, we
for the alternative drug. A schedule of 102 allocationreported the superior antiproteinuric effect of enalapril
numbers corresponding to similarly numbered drug sup-over nifedipine in these patients, despite similar BP con-
plies was provided for this purpose. Patients with mi-trol [14]. These patients have since been followed up at
croalbuminuria or macroalbuminuria were assigned anthree-month intervals while receiving their previously
allocation number in a descending manner, whereasassigned treatment for a mean total duration of 5.5 years.
those with normoalbuminuria were assigned an alloca-To test the hypothesis that for similar control of BP,
tion number in an ascending manner. The dosage wastreatment with enalapril was associated with superior
increased at four-week intervals during a 12-week titra-renoprotective effects compared with those with nifedi-
tion period to achieve a target supine systolic BP , 140pine, we performed a prospective cohort analysis to ex-
mm Hg at two- to four-hours postdose. Enalapril wasamine the determinants of renal function and clinical
increased stepwise from 10 mg daily to a maximum ofoutcomes in these patients.
40 mg daily. Nifedipine (slow release) was increased from
20 mg twice daily (40 mg per day) stepwise to a maximum
METHODS of 40 mg twice daily (80 mg per day). Following the 12-
The study was approved by the Clinical Research Eth- week titration period, indapamide, a thiazide-like di-
ics Committee of the Chinese University of Hong Kong, uretic, in a dosage of 2.5 mg daily, was added, followed
and its design has been previously described in detail by replacement with frusemide at 40 to 80 mg daily, if
[14]. It was a randomized, double-blind, placebo-con- the target BP was not achieved. All patients returned at
trolled study examining the effects of enalapril and nifed- three-month intervals for the examination of body
ipine (slow release) on UAE in hypertensive type 2 dia- weight and BP and measurement of routine biochemis-
betic patients. Inclusion criteria included a diagnosis of try, including 24-hour urinary collections. At one year,
type 2 diabetes, as defined by the World Health Organi- the majority (86%) of the nifedipine-treated patients
zation [20], and no history of ketosis. All patients were had achieved their target BP with a median daily dosage
treated with diet or oral agents, and none were receiving of 60 mg. By contrast, 76% of the enalapril-treated pa-
insulin treatment or lipid-lowering drugs at the time of tients required additional diuretic treatment compared
recruitment. None of the patients had a significant past with 14% in the nifedipine group [14].
medical history of cardiovascular disease, including After the one-year analysis, all patients were contin-
cerebrovascular accident, myocardial infarction, or un- ued on their previously assigned treatment with informed
consent. Because of the worsening of metabolic controlstable angina, or renal impairment, as defined by a
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in the diuretic-treated patients, diuretics were withdrawn (1/Cr) and the percentage of yearly change in 24-hour
CCr. All of the three-month 24-hour UAE measurementsfrom all patients if possible. Additional antihypertensive
drugs were used to optimize control of BP with the ex- were used to calculate the percentage yearly change in
UAE during the treatment period. All measurements ofception of use of ACE inhibitors in the nifedipine group.
These patients continued to be followed up at three- UAE, BP, fasting plasma glucose, HbA1c, TC, LDL-C,
HDL-C, and triglyceride were used to calculate the meanmonth intervals, with documentation of all clinical and
biochemical parameters. Drug compliance was repeat- values during the treatment period. UAE was logarith-
mically transformed because of its skewed distribution.edly reinforced by the research nurse and was confirmed
by tablet counting. Patients were considered to be com- All data are shown as mean 6 SD or geometric
mean 3/4 antilog SD as appropriate. Associations be-pliant if 80% or more of medications were taken.
tween variables were examined using partial correlation
Laboratory assays coefficients after adjustments for age and gender. Analy-
sis of covariance (ANCOVA), Student’s t-test, pairedThe laboratory assays have been described [14].
Plasma glucose was measured by a glucose oxidase t-test, chi-square test, and repeated-measures analysis
of variance (ANOVA) were used for between-groupmethod (Diagnostic Chemicals Ltd., Prince Edward Is-
land, Canada). The intra-assay coefficient of variation comparisons with adjustment for baseline values, as ap-
propriate. Stepwise regression analysis was used to deter-(CV) of glucose was 2% at 6.6 mmol/L. HbA1c was mea-
sured by an automated ion-exchange chromatographic mine the independent predictors for renal parameters
and clinical endpoints. The latter was defined as death,method (Bio-Rad Laboratory, Hercules, CA, USA). In-
terassay and intra-assay CV for HbA1c was #3.1% at cardiovascular (including stroke, myocardial infarction,
heart failure requiring hospitalization, revascularizationvalues below 6.5%. Total cholesterol (TC) and triglycer-
ide (TG) were assayed enzymatically with commercial procedures) and/or renal events (need for renal replace-
ment therapy or doubling of baseline plasma creatinine).reagents (Baker Instruments Corporation, Allentown,
PA, USA) on a Cobas Mira analyzer (Hoffman-La The Kaplan–Meier survival analysis was used to examine
Roche and Co., Basle, Switzerland). High-density lipo- the effects of albuminuric states on clinical endpoints.
protein cholesterol (HDL-C) was determined after frac- A P value , 0.05 was considered to be significant. All
tional precipitation with dextran sulfate-MgCl2. Low- analyses were performed using the Statistical Package
density lipoprotein cholesterol (LDL-C) was calculated for Social Sciences (SPSS version 6.0).
using the Friedewald’s formula [21]. Apolipoproteins
A-I (apo A) and apo B were assayed by radioimmunoas-
RESULTSsays (Array analyzer and reagents; Beckman Instruments
Table 1 summarizes the baseline clinical and biochemi-Inc., Bera, CA, USA). Interassay CVs were 1.9% for
cal characteristics of the 102 hypertensive type 2 diabeticTC, 1.9% for TG, 5.4% for HDL-C, 2.2% for apo A-I,
patients in 1989 [14]. Despite randomization, patientsand 2.8% for apo B. Plasma and urinary creatinine con-
assigned to receive enalapril treatment had a highercentrations were measured on a multichannel analyzer
mean age (by 4 years), serum TC, LDL-C, and apo B than(Parallel American Monitor, IN, USA). Urinary albumin
the nifedipine group at baseline. At one year, patientswas measured by immunoturbidimetry with intra-assay
treated with enalapril had a 54% reduction in 24-hourand interassay CVs of 3.3 and 6.7%, respectively. The
UAE compared with an 11% increase in the nifedipine-lowest detection limit was 2.5 mg/L [22].
treated group [14]. These patients were subsequently
Statistical analysis followed up for a mean period of 5.5 6 2.2 years.
Table 1 also summarizes the mean values of all clinicalThe primary end point of the one-year analysis was a
and biochemical parameters during the five-year treat-reduction in 24-hour UAE. The study was designed to
ment period among patients treated with either enalaprilgive a 90% power at 5% level to show that one drug
or nifedipine. The mean systolic BP and HbA1c werewas at least two times as effective as the other in reducing
higher during treatment with enalapril compared withUAE [14]. In the subsequent prospective cohort analysis,
nifedipine. Comparing baseline and mean values duringwe examined the effects of BP, metabolic indices, and
treatment, plasma creatinine increased and CCr de-assigned treatment on renal parameters. Patients were
creased in both groups, whereas 24-hour UAE signifi-divided into normoalbuminuric, microalbuminuric, and
cantly increased in the nifedipine group but remainedmacroalbuminuric groups based on two of three 24-hour
unchanged in the enalapril group.UAE measurements during the initial six-week run-in
By the end of the five-year study period four patientsperiod [23]. The mean values of all three measurements
had died, mainly because of cardiovascular events, andwere taken as the baseline values. The rate of deteriora-
with similar rates between the two treatment groups.tion of renal function was shown by the regression coef-
ficient (b) of the yearly plasma creatinine reciprocal Eleven patients had renal events, six in the enalapril
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Table 1. Clinical and biochemical characteristics of the 102 hypertensive, type 2 diabetic patients at baseline and during five-year treatment
with either enalapril or nifedipine
Total patients Enalapril group Nifedipine group
Variables (N 5 102) (N 5 50) (N 5 52) P value
Age years 58.069.8 60.069.3 56.269.9 0.047
Body mass index kg/m2 24.963.0 25.162.9 24.863.0 0.521
Follow-up period years 5.562.2 5.262.4 5.861.9 0.165
Systolic blood pressure mm Hg 169.2615.2 172.1616.5 166.5613.4 0.062
134.4610.8 137.0611.8d 132.269.4d 0.032
Diastolic blood pressure mm Hg 92.5610.9 92.5612.4 92.569.5 0.980
72.4611.4 72.1614.6e 72.667.8e 0.823
Mean arterial pressure mm Hg 118.169.6 119.0610.9 117.268.0 0.336
93.666.9 94.967.8e 92.565.9e 0.102
Fasting plasma glucose mmol/L 8.362.2 8.462.3 8.262.1 0.651
8.061.7 7.861.9 8.261.4 0.205
HbA1c % 7.5061.15 7.7061.17 7.3261.11 0.090
7.3060.89 7.5860.82 7.0660.88c 0.004
Total cholesterol mmol/L 5.7161.15 5.9761.34 5.4560.87 0.024
5.5960.91 5.6660.91 5.5460.92 0.544
Triglyceride mmol/L 1.9961.41 1.9361.38 2.0461.46 0.708
2.0361.27 2.0861.27 1.9861.28 0.720
HDL-C mmol/L 1.1760.31 1.1860.30 1.1760.33 0.782
1.2660.29 1.2360.29 1.2860.29d 0.469
LDL-C mmol/L 3.6261.11 3.9161.25 3.3460.89 0.010
3.4360.72 3.5160.71c 3.3660.73 0.292
Apolipoprotein A mg/dL 124.6625.9 125.1624.1 124.1627.6 0.847
Apolipoprotein B mg/dL 99.8623.2 106.6627.3 93.4616.4 0.004
Plasma creatinine lmol/L 85.3625.8 85.4623.8 85.1627.8 0.950
101.1639.7 103.5630.0e 99.0646.8e 0.589
Creatinine clearance mL/min 75.4626.7 73.7625.8 76.9627.6 0.542
63.5625.5 61.5622.9e 65.3627.7d 0.461
24-hour UAEa mg/day 75.9 3/4 6.7 73.4 3/4 6.9 78.5 3/4 6.6 0.859
89.4 3/4 6.7 78.8 3/4 6.5 100.6 3/4 7.0c 0.524
b-1/Cr 20.3562.83 20.1863.75 20.5161.53 0.563
For variables with 2 sets of values, the upper line shows the baseline values and the lower line shows the mean values during the treatment period.
a Data are mean 3/4 antilog sd
b P value comparing enalapril and nifedipine group
c P , 0.05
dP , 0.01
eP , 0.001 comparing baseline values and mean values within each treatment group (serum apo A and apo B were measured only at baseline)
Abbreviations are: HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; UAE, urinary albumin excretion; b-1/Cr, regression coefficient of
yearly plasma creatinine reciprocal.
group and five in the nifedipine group. Over 20% of buminuric group, there is no subsequent change in UAE
with either treatment. In the microalbuminuric group,patients required lipid-lowering drugs (enalapril group,
22%, N 5 11; nifedipine group, 25%, N 5 13, P 5 NS), treatment with enalapril was associated with a 13.0%
reduction in 24-hour UAE compared with baseline (fromand 12% were treated with insulin (enalapril group, 8%,
N 5 4; nifedipine group, 15%, N 5 8, P 5 NS). The 87.9 3/4 1.2 mg/day to 76.7 3/4 3.2 mg/day, P , 0.01).
This was in contrast to a 17.3% increase in the nifedipineuse of these drugs was similar between both treatment
groups. The majority of the enalapril-treated patients group (from 82 3/4 2 mg/day to 97 3/4 3.1 mg/day, P 5
NS). Less enalapril-treated microalbuminuric patients(68%, N 5 34) required additional antihypertensive
drugs for the control of BP compared with 46% (N 5 progressed to develop macroalbuminuria, and more pa-
tients reverted to become normoalbuminuria (Table 2).24, P , 0.05) in the nifedipine group. Except for the
initial 12-month study period (enalapril group, 76%; In the macroalbuminuric group, there was a trend for
24-hour UAE to decline after treatment with either ena-nifedipine group, 14%), the use of diuretics was similar
between the two groups (enalapril group, 12%, N 5 6; lapril or nifedipine, but the changes within or between
groups were not significant. When patients with macroal-nifedipine group, 17%, N 5 9, P 5 NS) after the one-year
analysis. Because of the protocol, none of the nifedipine- buminuria or microalbuminuria were combined for anal-
ysis, no significant changes in the 24-hour UAE duringtreated patients received ACE inhibitor therapy during
the five-year follow-up period. treatment were detected between these two treatment
groups. When all patients were included in the analysis,Table 2 shows the changes in albuminuric status in
these patients divided according to their assigned treat- more enalapril-treated patients reverted to become nor-
moalbuminuric (23.8 vs. 15.4%), and fewer of them de-ments and baseline albuminuric groups. In the normoal-
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Table 2. Progression of albuminuria in patients treated with enalapril or nifedipine based on their albuminuric state at baseline
Treatment
Baseline End of study Enalapril Nifedipine P value
Normoalbuminuria (N 5 43) 0.45
Normo- 14 (77.8%) 18 (72%)
Micro- 4 (22.2%) 5 (20%)
Macro- 0 2 (8%)
Microalbuminuria (N 5 34) 0.046
Normo- 5 (23.8%) 2 (15.4%)
Micro- 12 (57.1%) 7 (53.8%)
Macro- 4 (19.1%) 4 (30.8%)
Macroalbuminuria (N 5 25) 0.086
Normo- 0 0
Micro- 1 (9.1%) 3 (21.4%)
Macro- 10 (90.9%) 11 (78.6%)
Definition of albuminuria was based on two of three 24-hour urinary albumin excretions.
Fig. 1. Rates of deterioration of renal function, expressed as 24-hour
creatinine clearance, in hypertensive type 2 diabetic patients, subdivided
into normoalbuminuric (d), microalbuminuric (j), and macroalbumin-
Fig. 2. Effects of enalapril (h) and nifedipine ( ) treatment on pro-uric (m) groups based on two of three 24-hour urinary albumin excretion
gression of renal function, expressed as regression coefficient of yearlymeasurements at baseline.
plasma creatinine reciprocal (b-1/Cr) in hypertensive type 2 diabetic
patients subdivided into normoalbuminuric, microalbuminuric, and
macroalbuminuric groups based on two of three 24-hour urinary albu-
min excretion measurements at baseline.
veloped macroalbuminuria (19.1 vs. 30.8%) compared
with the nifedipine-treated patients (P , 0.05).
The clinical and biochemical characteristics of patients min/year), 22.9 6 4.9 mL/min/year (range 224.5, 7.3;
subdivided according to their baseline albuminuric status median 22.6 mL/min/year), and 22.5 6 9.0 mL/min/
were analyzed. Increasing albuminuria was associated year (range 220.7, 21.9; median 23.8 mL/min/year, P 5
with higher BP, worse metabolic indices, and renal func- 0.971). Figure 1 shows the progression of renal function,
tion, both at baseline and during the treatment period expressed as CCr, in these three groups of patients, irre-
(data not shown). The CCr in patients with normoalbumi- spective of their duration of follow-up. Using repeated-
nuria, microalbuminuria, and macroalbuminuria were measures ANOVA, macroalbuminuric patients had a
84.9 6 21.3, 77.5 6 27.3, and 56.0 6 24.8 mL/min (P , faster rate of decline in renal function than the other
0.001) at baseline, and their mean values during treat- two groups.
ment were 75.5 6 24.1, 63.5 6 21.3, and 41.9 6 18.5 mL/ Figure 2 shows the effects of nifedipine and enalapril
min (P , 0.001), respectively. The average rates of fall on the progression of renal function, as shown by the
of CCr in patients with normoalbuminuria, microalbumi- regression coefficients of yearly plasma creatinine recip-
nuria, and macroalbuminuria were, respectively, 22.7 6 rocal (b-1/Cr). In the macroalbuminuric group, enalapril
treatment was associated with stabilization compared4.2 mL/min/year (range 216.3, 7.9; median 2 2.7 mL/
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Table 3. Age and sex adjusted partial correlation coefficients between renal parameters and different variables at baseline and during
treatment in hypertensive type 2 diabetic patients
Mean creatinine Mean 24-hour Percentage Percentage
clearance during UAE during change per year change per year
b-1/Cr treatment treatment in CCr in UAE
Variables r P r P r P r P r P
BMI 0.071 0.516 0.278 0.010 20.046 0.678 0.072 0.674 20.012 0.943
Systolic BP 20.057 0.606 20.163 0.137 20.020 0.856 0.081 0.634 0.159 0.348
Diastolic BP 0.102 0.351 0.223 0.041 20.241 0.026 0.134 0.429 0.054 0.752
Fasting PG 20.215 0.048 20.268 0.013 0.378 ,0.001 0.039 0.819 20.245 0.144
HbA1c 20.307 0.004 20.222 0.041 0.279 0.010 0.122 0.472 20.065 0.701
TC 20.106 0.335 20.147 0.179 0.485 ,0.001 0.034 0.842 20.077 0.652
Triglyceride 20.210 0.053 20.081 0.464 0.326 0.002 0.227 0.177 0.054 0.750
HDL-C 0.131 0.234 20.170 0.120 0.158 0.148 0.167 0.323 20.179 0.289
LDL-C 20.018 0.869 20.050 0.650 0.244 0.025 20.170 0.319 20.036 0.834
Apo A 0.116 0.289 20.183 0.093 0.133 0.225 0.088 0.606 20.203 0.227
Apo B 20.198 0.070 20.096 0.383 0.430 ,0.001 20.070 0.682 0.054 0.751
Plasma creatinine 20.084 0.432 20.450 ,0.001 0.324 0.002 0.447 0.006 20.216 0.200
CCr 0.208 0.057 0.717 ,0.001 20.319 0.003 20.133 0.433 20.136 0.421
24-hour UAE 20.235 0.030 20.393 ,0.001 0.710 ,0.001 20.225 0.181 20.160 0.344
Mean values during
treatment
Systolic BP 20.391 ,0.001 20.319 0.003 0.330 0.002 20.120 0.484 0.192 0.256
Diastolic BP 20.089 0.419 0.138 0.209 20.097 0.378 20.014 0.935 0.180 0.288
Fasting PG 20.132 0.228 20.039 0.726 20.039 0.723 20.514 0.001 0.084 0.621
HbA1c 20.156 0.154 20.207 0.057 0.121 0.269 20.300 0.071 0.218 0.195
TC 20.039 0.724 20.127 0.247 0.429 ,0.001 20.219 0.180 0.132 0.422
Triglyceride 20.183 0.094 20.203 0.063 0.257 0.018 20.146 0.377 0.394 0.013
HDL-C 0.243 0.025 20.030 0.788 20.002 0.983 20.003 0.988 20.332 0.039
LDL-C 20.048 0.660 0.031 0.788 20.002 0.983 20.115 0.485 0.194 0.236
Plasma creatinine 20.386 ,0.001 0.031 0.778 0.263 0.015 0.057 0.730 0.323 0.045
b-1/Cr — — 0.295 0.006 20.321 0.003 0.267 0.091 0.021 0.897
CCr 0.295 0.006 — — 20.377 ,0.001 0.345 0.031 20.344 0.032
24-hour UAE 20.321 0.003 20.377 ,0.001 — — 20.353 0.027 0.594 ,0.001
Percentage
change per year
in CCr 0.267 0.091 0.345 0.031 20.353 0.027 — — 20.523 0.001
Percentage
change per year
in UAE 0.021 0.897 20.344 0.032 0.594 ,0.001 20.523 0.001 — —
Abbreviations are: BMI, body mass index; BP, blood pressure; PG, plasma glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; HDL-C and LDL-C, high
and low density lipoprotein cholesterol; Apo A and Apo B, apolipoprotein A and B; CCr, creatinine clearance; UAE, urinary albumin excretion; b-1/Cr, regression
coefficient of yearly plasma creatinine reciprocal.
with a decline in renal function in the nifedipine group assigned treatment with either enalapril (1) or nifedipine
(P , 0.05), after adjustment for baseline values. When (0) on renal parameters and clinical outcomes. Twenty-
patients with microalbuminuria or macroalbuminuria four–hour UAE during treatment was independently as-
were combined for analysis, renal function also tended sociated with UAE, fasting plasma glucose, serum apo
to stabilize in the enalapril group compared with a de- A at baseline, and plasma creatinine and CCr during treat-
cline in the nifedipine group, although this did not reach ment. The mean CCr during treatment was determined
statistical significance (b-1/Cr: 0.46 6 2.94 L/mmol/year 3 by age, male gender, fasting plasma glucose, UAE, and
1023 vs. 20.93 6 2.01 L/mmol/year 3 1023, P 5 NS). CCr at baseline. The rate of change of plasma creatinine
Table 3 summarizes the age- and sex-adjusted partial reciprocal (b-1/Cr) was independently associated, with
correlation coefficients between renal parameters and a mean CCr during treatment and baseline HbA1c. The
different variables at baseline and during treatment. Re- clinical outcomes (death, cardiovascular events, or renal
nal function, as indicated by b-1/cr, mean 24-hour UAE events) were independently related to mean LDL-C and
and CCr during treatment and yearly percentage changes HDL-C, baseline UAE, and mean CCr during treatment.
in CCr and UAE, were closely associated with BP, gly-
cemic, and lipid indices at baseline and during treatment.
DISCUSSIONTable 4 summarizes the results of the stepwise regression
Renal failure is a leading cause of early mortality andanalysis examining the effects of these variables, includ-
ing age, duration of disease, metabolic control, BP, and morbidity in diabetic patients. Type 2 diabetes is the
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Table 4. Multiple regression analysis (stepwise forward) examining the effects of age, sex, duration of follow-up, metabolic control (fasting
plasma glucose, HbA1c, lipid parameters, plasma creatinine concentration, 24-hour UAE and creatinine clearance), blood pressure and
assigned treatment with either enalapril (1) or nifedipine (0) on renal parameters and clinical outcomes
b P value
b-1/Cr (R2 5 0.195, F 5 11.93, P , 0.001)
Mean plasma creatinine concentration during treatment 20.310 0.002
Baseline HbA1c 20.285 0.004
Mean creatinine clearance during treatment (R2 5 0.715, F 5 46.73, P , 0.001)
Age 20.262 ,0.001
Baseline creatinine clearance 0.613 ,0.001
Baseline 24-hour UAE 20.194 0.001
Baseline fasting plasma glucose 20.120 0.042
Male sex 20.114 0.049
Mean 24-hour UAE during treatment (R2 5 0.699, F 5 34.99, P , 0.001)
Baseline 24-hour UAE 0.511 ,0.001
Mean creatinine clearance during treatment 0.399 ,0.001
Mean plasma creatinine concentration during treatment 0.359 ,0.001
Baseline creatinine clearance 0.291 0.005
Baseline apolipoprotein A 0.172 0.007
Baseline fasting plasma glucose 0.160 0.013
Percentage change per year in UAE (R2 5 0.516, F 5 30.59, P , 0.001)
Baseline 24-hour UAE 1.444 ,0.001
Mean 24-hour UAE during treatment 21.409 ,0.001
Baseline LDL-C 0.171 0.025
Clinical outcomes (death, cardiovascular events, and renal events) (R2 5 0.176, F 5 60.81, P , 0.001)
Mean creatinine clearance during treatment 20.211 0.006
Mean LDL-C 2.426 0.018
Mean HDL-C 28.797 0.033
Baseline UAE 0.002 0.047
Abbreviations are: HbA1c, glycated hemoglobin; UAE, urinary albumin excretion; b-1/Cr, regression coefficient of yearly plasma creatinine reciprocal after
adjustment for baseline values; CCr, creatinine clearance; LDL-C, low-density lipoprotein cholesterol.
predominant form of the disease, and its prevalence is clinical trials, the advantageous cardioprotective and vas-
culoprotective effects of ACE inhibitors over calciumincreasing rapidly, especially in developing countries
[24]. There is also evidence suggesting that non-Cauca- channel-blocking agents in these high-risk patients have
been confirmed [18, 19]. Although the ABCD trial aimedsian type 2 diabetic patients are at increased risk of renal
disease relative to Caucasian patients [25, 26]. Hence, to examine the renal effects of these treatments, the
study failed to reach a conclusion because of its earlytype 2 diabetes is the single most important cause of
end-stage renal disease worldwide, and its incidence is discontinuation [19]. In patients with chronic renal fail-
ure from miscellaneous causes, treatment by ACE inhibi-expected to continue to rise [27, 28]. Although the anti-
proteinuric effect of ACE inhibitors over other antihy- tion has been shown to attenuate the rate of deterioration
of renal function [32–34]. Indeed, in one of these studies,pertensive drugs has been repeatedly demonstrated [9],
the renoprotective effects of these agents have only been one of the treatment arms had to be discontinued prema-
turely because of the clear renoprotective effects of rami-confirmed in type 1 [10] and normotensive type 2 diabetic
patients [11, 12]. pril in patients with nondiabetic proteinuria .3 g/day
[33]. Despite these encouraging results, in view of theThere is a high prevalence of hypertension, ranging
from 30 to 90%, depending on definitions, in type 2 metabolic milieu and multiple medical problems in the
majority of type 2 diabetic patients, findings from otherdiabetes [29, 30]. Despite the magnitude of this health
problem, there are only a few long-term studies, lasting patient groups may not necessarily be applicable to the
majority of hypertensive type 2 diabetic patients.for one year or more, comparing the renal effects of
ACE inhibitors with other antihypertensive drugs in hy-
ACE inhibition in type 2 diabetic patientspertensive type 2 diabetic patients [13–15]. In the more
recently published studies, results were again inconclu- In a three-year study comparing the renal effects of
cilazapril and amlodipine, both drugs had similar effectssive. In the UKPDS, aggressive control of BP alone was
associated with improved clinical outcomes, which were on renal clearance in 44 hypertensive type 2 diabetic
patients with or without microalbuminuria [13]. In thenot different between patients treated with captopril and
those with atenolol [17]. Other studies have also identi- recently published ABCD trial that aimed to examine
the renal effects of enalapril and nosoldipine in type 2fied BP, plasma glucose, and lipid levels as the major
determinants for the progression of renal function in diabetic patients, the trial had to be discontinued prema-
turely in the hypertensive arm because of increased mor-type 2 diabetic patients [31]. In two recent randomized
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tality and cardiovascular morbidity in the nosoldipine of several ongoing long-term prospective randomized
studies comparing angiotensin II antagonists and othergroup [19]. In another three-year study comparing the
effects of fosinopril and amlodipine in hypertensive type antihypertensive agents in type 2 diabetic patients with
renal impairment are awaited with much interest.2 diabetic patients with normoalbuminuria, treatment
with fosinopril was associated with a greater reduction
ACE inhibition and progression of renal functionin albuminuria and a lower risk of cardiovascular deaths
and events compared with amlodipine [18]. However, Regarding the progression of renal function, our nor-
moalbuminuric and microalbuminuric patients had simi-in all of these relatively short-term studies, the renal
protective effects of ACE inhibitors remained inconclu- lar rates of decline in CCr once satisfactory BP control had
been achieved. Conversely, macroalbuminuric patientssive.
Our cohort is a typical population of type 2 diabetic showed a substantially greater and relentless deteriora-
tion in CCr, despite similar control of BP. Given thepatients with coexisting hypertension [35, 36]. In keeping
with most published studies, approximately 50% of our known adverse effects of angiotensin II on renal hemo-
dynamics and tissue growth, as well as the close relation-patients had normoalbuminuria, 25% had microalbumi-
nuria, and 25% had macroalbuminuria. Increasingly un- ships between albuminuria and progression of renal func-
tion in most reports [41], one would expect beneficialfavorable metabolic profiles, BPs, and renal function
were associated with increasing proteinuria [36, 37]. In effects of ACE inhibitors treatment on renal function in
these hypertensive diabetic patients.1989, when our study was designed and conducted, the
primary end point was reduction in UAE, and we found However, in this study, there was some discordance
between the rate of decline in renal function and theafter one year that enalapril treatment was associated
with a greater reduction (254%) in albuminuria than antiproteinuric responses to treatment. At a similar BP
control level, progression of renal function was retardednifedipine (111%). However, the plasma creatinine in-
creased in both groups and more so in the enalapril- by enalapril in only the macroalbuminuric patients,
whereas proteinuria was improved by enalapril in onlytreated patients. The latter rise was probably caused
by the rapid fall in BP following the administration of the microalbuminuric patients. In the macroalbuminuric
patients, treatment with enalapril reduced the rate ofdiuretics to the majority of enalapril-treated patients,
making the one-year results inconclusive regarding the decline in renal function, expressed as b-1/Cr, although
the antiproteinuric effects were less impressive than thatrenoprotective effects of these agents [14]. In the three-
year study comparing the renal effects of cilazapril versus in the microalbuminuria group. The latter might be due
to the large interindividual and intraindividual variationsamlodipine in type 2 diabetic patients, two phases of
progression of renal function were reported. The first in UAE among these patients with heavy proteinuria.
However, the beneficial effects of ACE inhibitor therapyphase was a more rapid decline in the glomerular filtra-
tion rate (GFR), which was proportional to the magni- were easier to detect in these patients in whom renal
function tended to decline more rapidly. On the othertude of fall in BP. The second phase represented a slower
rate of decline in GFR that was inversely proportional hand, the improvement in albuminuria observed with
enalapril treatment in the microalbuminuric group wasto the fall in BP [13]. A similar pattern was observed in
our study, which emphasizes the importance of long- not accompanied by a beneficial effect on renal function.
Given the relatively long natural history of diabetic pro-term follow-up in the assessment of renal function.
teinuria, the five-year follow-up period might not be
ACE inhibition and albuminuric status sufficiently long enough for these antiproteinuric effects
to be translated into renoprotection. However, in spiteIn this five-year prospective study, the anti-albumin-
uric effects of enalapril were less marked compared with of the apparent discordance, when the microalbuminuric
and macroalbuminuric patients were combined as athose reported in the one-year analysis (213 vs. 254%).
Although some of these differences in changes in UAE group, there was a trend for renal function to stabilize
in the enalapril group but deteriorate in the nifedipinemay represent regressions to the mean, incomplete sup-
pression of plasma angiotensin II levels during chronic group. Because progression of renal function was slow
in normoalbuminuric patients, the change in their renalACE inhibitor therapy may also be important [38, 39].
The latter is mainly due to the presence of alternative parameters did not reach statistical significance in our
study, despite the relatively long mean follow-up periodnon-ACE pathways for the conversion of angiotensin I
to angiotensin II, such as the chymase pathway [40]. of five years. Nevertheless, when all patients were in-
cluded in the analysis, more enalapril-treated patientsDespite the smaller magnitude of the overall reduction
in UAE with prolonged follow-up, patients treated with reverted to normoalbuminuria, and fewer of them devel-
oped macroalbuminuria compared with the nifedipine-enalapril, especially those with microalbuminuria, were
less likely to progress to macroalbuminuria than the treated patients.
Other points also need to be considered when thesenifedipine group. Against this background, the results
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results are interpreted. By chance and despite random- ity [18, 19] may in part be mediated by effects on protein-
uria and hyperlipidemia [51, 52]. In the present study,ization in a double-blind and placebo-controlled manner,
our enalapril-treated patients had a higher mean age and the use of lipid-lowering drugs was similar between the
enalapril and nifedipine group. Although the macroalbu-worse lipid profiles than the nifedipine-treated patients
at baseline [42]. The enalapril-treated patients were minuric patients had the highest frequency of clinical
endpoints, we were unable to show a superior effect ofmore likely to be treated with diuretics initially and had
their antihypertensive therapy changed during the subse- enalapril over nifedipine in reducing these events.
quent follow-up. As a result, these enalapril-treated pa-
Glycemic control and renal functiontients did not have as good BP and metabolic control as
In the present study, glycemic control, including fast-the nifedipine group. All of these factors might have
ing plasma glucose and HbA1c, was also an importantcontributed to the less than expected beneficial effects
determinant of the progression of renal function, alongof ACE inhibitor treatment observed in this study.
with age, male gender, and lipid indices. The beneficialHence, overall, our findings corroborate other studies,
effects of optimal glycemic control on microvascularwhich have confirmed the renoprotective effects of ACE
complications, including proteinuria, have been showninhibitors in patients with nondiabetic renal disease [32–
in type 1 [6] and type 2 diabetic patients [7, 53]. In a34], as well as in type 1 [10] and normotensive type 2
separate cohort analysis, our group has previously showndiabetic patients [11, 12]. However, it is important to
that the mortality rate of our type 2 diabetic patientsnote that there was a tendency for renal function to
was 3% per year, mainly due to cardiovascular eventsdecline more rapidly among our normoalbuminuric pa-
or renal failure. Fasting plasma glucose and albuminuriatients treated with enalapril compared to the nifedipine
were the independent predictors of death [54]. Theregroup. In this respect, although hypertension and pro-
is increasing evidence indicating direct toxic effects ofteinuria frequently coexist in type 1 diabetic patients,
hyperglycemia on cellular functions. These include acti-many type 2 diabetic patients have hypertension in the
vation of the sorbitol pathway [55] and alteration ofabsence of proteinuria. Some of these patients may have
intracellular signaling pathways, such as increased ex-renovascular disease, and the use of ACE inhibitors may
pression of protein kinase C leading to endothelial dys-reduce GFR further [27, 43–45]. More studies are re-
function, activation of cytokines and disturbed cellularquired to clarify these diversified responses to antihyper-
growth [56]. These factors, together with the frequenttensive treatments in type 2 diabetic patients with differ-
coexistence of other risk factors such as hypertension,ent degrees of albuminuria.
obesity, and hyperlipidemia, may all contribute to the
Hyperlipidemia and renal function increased mortality and morbidity, as well as deteriora-
tion of renal function in type 2 diabetic patients [1].The pathogenesis of diabetic proteinuria is complex
and involves metabolic, hemodynamic, growth, and ge-
netic factors [46]. In this study, apart from albuminuria, CONCLUSION
renal function was also related to BP, glycemic and lipid
In this prospective cohort analysis involving 102 hyper-
indices including serum apo B, LDL-C, triglyceride, and
tensive type 2 diabetic patients with varying degrees of
reduced HDL-C concentrations. These findings there- albuminuria followed for a mean duration of five years,
fore are in accordance with those in the five-year study we have observed the importance of good metabolic and
of Ravid et al examining the effects of enalapril versus BP control regarding the progression of albuminuria and
placebo in normotensive type 2 diabetic patients. In these renal function. Patients with macroalbuminuria had the
latter patients, changes in albuminuria were also closely worst clinical outcomes, including cardiovascular events,
associated with changes in lipid indices including reduced as well as an accelerated deterioration in renal function.
HDL-C and increased TC [31, 47]. Treatment with enalapril was associated with a greater
There is both clinical and experimental evidence dem- reduction in albuminuria than nifedipine, especially in
onstrating the relationship between hyperlipidemia and the microalbuminuric patients. In the macroalbuminuric
proteinuria. Although treatment with HMG Co-A re- patients, the rate of deterioration in renal function was
ductase inhibitors has been shown to reduce proteinuria also attenuated by treatment with enalapril.
[48–50], their long-term renal effects remain to be estab-
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